Fujifilm Kyowa Kirin Biologics: joint venture with AstraZeneca to develop and commercialise anti-VEGF biosimilar

Fujifilm Kyowa Kirin Biologics has announced that they will jointly develop with AstraZeneca FKB238, a biosimilar version of bevacizumab (Avastin), an anti-VEGF1 humanized monoclonal antibody with established efficacy across a range of cancers including colorectal and non-small cell lung cancer2.

China Bio news release, Aug. 8, 2015

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny